pandem
normal
suscept
oseltamivir
variant
harbor
cac
tac
mutat
exhibit
resist
describ
use
combin
reversetranscript
polymeras
chain
reaction
rtpcr
pyrosequenc
approach
identifi
residu
total
specimen
test
method
randomli
select
clinic
specimen
posit
cellcultur
supernat
center
diseas
control
prevent
cdc
resist
suscept
strain
assay
detect
clinic
respiratori
sampl
oseltamivirresist
strain
cdc
remain
clinic
suscept
cdc
specimen
wildtyp
sanger
sequenc
confirm
result
select
isol
rtpcrpyrosequenc
method
highli
specif
produc
amplicon
valid
sequenc
sampl
contain
virus
bacteria
find
suggest
method
provid
rapid
tool
detect
high
sensit
potenti
benefit
patient
care
pandem
influenza
predomin
viru
worldwid
influenza
season
claim
thousand
live
sinc
gener
resist
adamantan
leav
neuraminidas
na
inhibitor
drug
class
avail
antivir
therapi
deyd
gubareva
deyd
et
al
oseltamivir
wide
use
na
inhibitor
treatment
influenza
deyd
et
al
howev
resist
influenza
variant
spread
worldwid
season
sheu
et
al
increas
oseltamivir
use
pandem
season
rais
concern
resist
variant
may
emerg
inde
resist
case
report
worldwid
cdc
wang
et
al
includ
resist
isol
detect
low
oseltamivirusag
region
hurt
et
al
oseltamivir
resist
associ
mutat
na
type
residu
impact
catalyt
site
maurerstroh
et
al
na
number
commonli
report
na
mutat
chang
histidin
cac
wild
type
codon
tyrosin
tac
mutant
type
codon
confer
viral
resist
oseltamivir
cdc
renaud
et
al
wang
et
al
mutat
neighbor
activ
site
might
alter
oseltamivir
suscept
data
support
inconclus
sheu
et
al
rapid
detect
oseltamivir
resist
clinic
essenti
direct
appropri
care
pandem
season
na
inhibit
assay
consid
gold
standard
gubareva
et
al
mungal
et
al
time
consum
technic
complex
make
impract
use
clinic
laboratori
mismatch
amplif
mutat
cycl
probe
method
offer
molecular
altern
hata
et
al
suzuki
et
al
specif
viru
detect
use
genotypicspecif
primer
may
use
operario
et
al
procedur
straightforward
clinic
laboratori
realtim
reversetranscript
polymeras
chain
reaction
rtpcr
could
use
detect
bolotin
et
al
renaud
et
al
assay
howev
either
season
influenza
need
reaction
multipl
primer
data
interpret
indirect
describ
molecular
assay
use
rtpcr
coupl
pyrogram
procedur
rtpcrpyroseq
detect
na
residu
assay
short
analyt
time
rel
simpl
perform
provid
direct
result
character
oseltamivir
resist
two
viral
specimen
type
use
first
compris
clinic
respiratori
sampl
collect
novemb
januari
throughout
continent
unit
state
specimen
transport
viralchlamydialmycoplasma
transport
media
bd
franklin
lake
nj
usa
second
specimen
type
compris
cell
cultur
supernat
viral
type
phenotyp
drug
resist
character
center
diseas
control
prevent
cdc
resist
suscept
oseltamivir
clinic
specimen
maintain
cell
cultur
supernat
rna
extract
presenc
type
virus
season
influenza
patient
specimen
determin
use
influenza
real
time
rtpcr
kit
focu
diagnost
cypress
ca
usa
abi
realtim
pcr
system
abi
foster
ca
usa
accord
manufactur
instruct
viral
rna
specimen
extract
nucleic
acid
extract
kit
magna
system
roch
appli
scienc
mannheim
germani
follow
manufactur
instruct
use
viral
identif
well
na
sequenc
detect
clinic
specimen
use
na
sequenc
detect
randomli
select
specimen
pool
studi
clinic
specimen
posit
specimen
neg
posit
season
influenza
test
rna
extract
describ
use
na
sequenc
detect
na
residu
detect
sequenc
rtpcr
follow
pyrogram
procedur
rtpcrpyroseq
rtpcr
perform
use
onestep
rtpcr
kit
qiagen
valencia
ca
usa
whopublish
primer
deyd
et
al
synthes
invitrogen
carlsbad
ca
usa
briefli
sampl
rna
extract
per
reaction
amplifi
atc
thermal
cycler
nyxtech
san
diego
ca
usa
follow
profil
min
follow
min
amplif
cycl
min
final
incub
result
amplicon
visual
egel
system
invitrogen
pyrosequenc
perform
pyromark
id
system
qiagen
whopublish
sequenc
primer
invitrogen
golden
reagent
kit
qiagen
nucleotidedispens
cycl
result
na
sequenc
cac
defin
suscept
tac
resist
oseltamivir
fig
entir
process
rna
extract
sequenc
result
requir
less
h
sanger
sequenc
method
employ
verifi
rtpcrpyroseq
result
select
rna
extract
specimen
pool
describ
includ
oseltamivirresist
isol
cdc
na
gene
sequenc
viral
strain
genbank
number
term
fig
use
refer
templat
primer
product
sequenc
align
two
pair
primer
locat
bp
upstream
downstream
residu
develop
seqwright
houston
tx
usa
rtpcr
sanger
sequenc
first
pair
second
pair
synthes
integr
dna
technolog
coralvil
ia
usa
sigma
woodland
tx
usa
dna
cycl
sequenc
perform
use
bigdy
termin
v
chemistri
abi
primer
sequenc
delin
align
repres
sequenc
sanger
method
sequenc
rtpcrpyroseq
method
p
refer
sequenc
genbank
number
describ
materi
method
two
cluster
mutat
residu
underlin
highlight
nonclust
mutat
detect
sanger
sequenc
nearest
residu
either
direct
shown
highlight
base
call
perform
use
autom
fluoresc
dna
sequenc
abi
model
carlsbad
ca
usa
sequenc
assembl
edit
sequench
softwar
genecod
ann
arbor
mi
usa
sequenc
data
evalu
use
score
criteria
codoncod
dedham
usa
standard
refer
lineag
produc
identif
realtim
rtpcr
cycl
threshold
ct
valu
viral
tcid
ml
titer
viral
strain
influenza
viru
nymc
courtesi
focu
diagnost
determin
detect
limit
viral
specimen
serial
dilut
replic
viral
specimen
tabl
rtpcr
success
amplifi
target
na
gene
fragment
contain
codon
viralposit
specimen
pyrosequenc
procedur
synthes
sequenc
amplicon
detect
codon
pandem
specimen
test
rtpcrpyroseq
method
detect
wildtyp
codon
cac
clinic
sampl
mutant
tac
genotyp
result
rtpcrpyroseq
concord
phenotyp
cell
cultur
supernat
cdc
identifi
wildtyp
codon
oseltamivirsuscept
sampl
mutanttyp
codon
oseltamivirresist
sampl
fig
sanger
sequenc
produc
valid
sequenc
align
refer
templat
fig
specimen
test
sanger
sequenc
identifi
oseltamivirresist
mutant
type
tac
oseltamivirresist
supernat
consist
rtpcrpyroseq
result
identifi
suscept
wildtyp
codon
cac
remain
fortysix
specimen
also
confirm
rtpcrpyroseq
result
singl
clinic
specimen
harbor
oseltamivirresist
viru
identifi
complet
sanger
sequenc
analysi
thu
test
method
sanger
sequenc
also
detect
anoth
cluster
mutat
clinic
sampl
result
substitut
aspart
acid
gat
asparagin
aat
residu
posit
mutat
correl
residu
observ
sixteen
individu
mutat
observ
viral
isol
mutat
nearest
residu
bp
upstream
bp
downstream
demonstr
fig
standard
linear
regress
ct
valu
log
tcid
ml
gener
test
known
viral
tcid
ml
dilut
realtim
rtpcr
ct
valu
x
log
tcid
ml
maximum
detect
ct
valu
rtpcrpyroseq
na
codon
rang
averag
detect
ct
valu
tabl
base
equat
detect
ct
valu
equival
mean
viral
concentr
rang
tcid
ml
detect
limit
tcid
plaqu
form
unit
pfu
ml
pfuml
tcid
ml
per
reaction
averag
test
valid
panel
diagnost
hybrid
produc
similar
detect
limit
reach
virus
per
reaction
data
shown
rtpcrpyroseq
interand
intrarun
assay
dilut
group
sampl
valid
panel
produc
dna
amplicon
size
sequenc
result
rtpcrpyroseq
method
produc
amplicon
valid
sequenc
season
influenza
noninfluenza
virus
bacteria
test
studi
tabl
detect
mixtur
oseltamivirsuscept
viral
suspens
singl
clinic
sampl
contain
mutat
man
california
immunosuppress
due
diffus
larg
bcell
lymphoma
pulmonari
fibrosi
chemotherapi
prednison
infect
first
diagnos
use
rtpcr
decemb
oral
oseltamivir
initi
day
switch
intraven
peramivir
mg
daili
day
later
sign
improv
oseltamivir
therapi
fda
respiratori
specimen
collect
januari
posit
mutat
pyrosequenc
viru
detect
neg
januari
may
patient
recov
unev
detect
drugresist
viral
variant
patient
care
becom
extrem
import
influenza
season
especi
sever
influenza
case
immunocompromis
patient
sever
molecular
approach
report
detect
describ
introduct
section
method
use
realtim
rtpcr
report
detect
mutat
may
good
either
season
influenza
bolotin
et
al
surveil
applic
deyd
et
al
pyrosequenc
molecular
marker
detect
prove
use
surveil
laboratori
couturi
et
al
deng
et
al
deyd
et
al
rtpcrpyroseq
method
describ
design
clinic
laboratori
applic
result
studi
verifi
sanger
sequenc
demonstr
provid
reliabl
detect
na
residu
sequenc
analyt
time
h
rapid
assess
oseltamivir
suscept
clinic
import
tradit
approach
requir
timeconsum
labori
viral
cultiv
lackenbi
et
al
rtpcrpyroseq
method
specif
produc
amplif
valid
sequenc
test
virus
bacteria
tabl
analyt
sensit
rtpcrpyroseq
residu
sequenc
detect
tcid
ml
tabl
similar
report
pyrosequencingbas
detect
season
drugresist
mutat
lackenbi
et
al
sensit
level
suffici
properli
sampl
posit
clinic
specimen
indic
detect
na
sequenc
test
clinic
specimen
compar
sanger
sequenc
pyrosequenc
method
save
time
cost
sanger
sequenc
respect
pyrosequenc
approach
thu
specif
quick
reliabl
sensit
moneysav
key
trait
clinic
laboratori
use
may
even
applic
develop
countri
although
mutant
readili
detect
wildtypemut
mixtur
determin
actual
viral
concentr
sought
experi
laboratori
safeti
issu
viral
propag
requir
need
experi
prevent
extens
test
ratio
mixtur
howev
cell
cultur
follow
viral
rna
extract
use
studi
type
sampl
sourc
treat
use
condit
thu
assum
ratio
like
proport
viral
densiti
mixtur
result
indic
method
abl
detect
posit
result
mutat
viral
popul
turn
entir
mutant
form
catalyticsit
mutat
wide
report
influenza
specimen
season
deyd
gubareva
report
oseltamivirresist
virus
sheu
et
al
data
indic
cdcorigin
clinic
oseltamivirresist
isol
posit
support
mutat
key
oseltamivirresist
molecular
marker
provid
clinic
import
inform
patient
care
sole
clinic
sampl
harbor
studi
immunosuppress
man
associ
clinic
resist
oseltamivir
resist
develop
pattern
consist
previou
report
dharan
et
al
graitcer
et
al
hurt
et
al
b
describ
rapid
emerg
resist
immunocompromis
patient
receiv
oseltamivir
mutat
detect
na
gene
occur
protein
surfac
appar
affect
drug
bind
site
serious
affect
drug
suscept
maurerstroh
et
al
residu
report
elsewher
associ
antibodi
bind
site
na
surfac
thu
may
littl
impact
oseltamivir
bind
site
maurerstroh
et
al
wagner
et
al
howev
function
analysi
nonclust
mutat
beyond
scope
studi
detect
identif
singl
mutat
may
limit
factor
assay
sinc
oseltamivir
resist
mutat
could
overlook
detect
recent
report
indic
dual
mutant
variant
extrem
high
oseltamivir
resist
hurt
et
al
meanwhil
small
number
specimen
test
run
certainli
decreas
assay
effici
increas
suppli
labor
cost
precaut
measur
biosafeti
cross
contamin
implement
prevent
laboratoryassoci
infect
laboratori
personnel
test
discrep
process
patient
specimen
rtpcrpyroseq
method
detect
oseltamivir
resist
among
virus
well
adapt
clinic
laboratori
yield
reproduc
result
within
short
time
could
greatli
benefit
patient
care
upcom
influenza
season
